VTGN (Vistagen Therapeutics) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


VTGN Vistagen Therapeutics Inc VTGN
40 GF Score
Price $0.67
GF Value $2.20
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vistagen Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

VTGN vs PLUR, PTN, CLRB: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Vistagen Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vistagen Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Vistagen Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


VTGN
40GF Score
Vistagen Therapeutics Inc VTGN
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vistagen Therapeutics (VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of $0.67 is trading 69.7% below its estimated GF Value™ of $2.20. GuruFocus considers Vistagen Therapeutics to be Possible Value Trap.

Key valuation signals for VTGN:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $2.20 vs. price of $0.67 (69.7% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score

Get the complete analysis for VTGN

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price
$2.20
GF Value